In connection with the implementation by the Ordering Party of the project entitled “Use of matrix metalloproteinase inhibitor to develop an innovative therapy of preventing the development of post-traumatic and post-stroke epilepsy” /POIR.01.01.01-00-0235/20-00/ within Measure 1.1. R&D projects of enterprises, Submeasure 1.1.1 Industrial research and development work implemented by enterprises, co-financed by the European Regional Development Fund, and also in connection with the obligation to apply the principle of competitiveness,
Pikralida sp. z o.o. invites you to submit offers for performing Preclinical Safety Assessment Program for the drug candidate PKL-021.
In connection with the requests from the bidders on the possibility of extending the deadline for concluding the offer, we inform you that the deadline for concluding the offer has remained due until April 8, 2022.
Bids should be submitted electronically to the following e-mail address: pricing_offers@pikralida.eu or via the competitiveness database (link below), in person, by post or by courier to the address of our registered office (date of receipt shall be considered) by April 8, 2022, until: 11:59 pm.
The request for proposal No. 15/2022 and template documents have been published in the Competitiveness Database:
https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl/ogloszenia/95887